Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A First-in-human, Phase 1/2, Multicenter, Open-label, Dose Escalation and Expansion Study to Evaluate the Safety, Pharmacokinetics, and Antitumor Activity of ADCE-D01, a Humanized Anti-human uPARAP Antibody Linked to a Topoisomerase I Inhibitor, in Patients With Metastatic and/or Unresectable Soft Tissue Sarcoma

NCT06797999 is registered in ClinicalTrials.gov with Adcendo ApS as lead sponsor.

NCT NCT06797999
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06797999 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A First-in-human, Phase 1/2, Multicenter, Open-label, Dose Escalation and Expansion Study to Evaluate the Safety, Pharmacokinetics, and Antitumor Activity of ADCE-D01, a Humanized Anti-human uPARAP Antibody Linked to a Topoisomerase I Inhibitor, in Patients With Metastatic and/or Unresectable Soft Tissue Sarcoma
Lead sponsor
Adcendo ApS
Phase
Phase 1/2
Overall status
Recruiting
Start date
June 5, 2025
Completion date
February 27, 2029
Enrollment
270 (estimated)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic soft tissue sarcoma, unresectable soft tissue sarcoma